Knut och Alice Wallenbergs Stiftelse’s Post

Researchers at Lund University in Sweden have developed a digital cognitive test for diagnosing Alzheimer's disease that is intended for use in primary care. “This digital test, which patients perform on their own with minimal involvement from healthcare personnel, improves the primary care physician's ability to determine who should be further examined by blood tests for Alzheimer's pathology early in the investigation phase,” says Professor Oskar Hansson, who led the study alongside Pontus Tideman. “Primary care does not have the resources, time or specialist knowledge to investigate possible Alzheimer's disease in the same way as specialised memory clinics. And this is where a digital cognitive test can make the biggest difference,” says Oskar Hansson, professor of neurology at Lund University. Research supported by Knut and Alice Wallenberg Foundation https://lnkd.in/diQQeBeS #research #medicine #Alzheimers #Alzheimer Lund University Oskar Hansson

We are excited to announce our recent publication in Neuropharmacology, highlighting an important finding on the role of Metoprolol, a widely used antihypertensive β-blocker, in exacerbating dementia. This work reflects our efforts to strengthen collaboration between UAE University and Cairo University. https://lnkd.in/ddY-4Wgu #Neuropharmacology #DementiaResearch #BetaBlockers #UAEU #CairoUniversity #ResearchCollaboration

A new blood test for #Alzheimer’s is being trialled across 20 #NHS memory clinics in the UK, aiming to boost diagnostic accuracy from 70% to over 90%. Led by UCL and backed by Alzheimer's Society and Alzheimer's Research UK, this could transform early detection and care. Learn more: https://lnkd.in/e5sjj_Vx #Diagnostics #Alzheimers #DementiaAwareness #HealthcareInnovation #MedicalResearch #UCL #Biomarkers #EarlyDiagnosis #Neuroscience #ADAPTTrial

A simple vision test could detect Alzheimer's up to 12 years before memory loss begins. Yes, there is strong evidence that a simple vision test could detect Alzheimer’s up to 12 years before memory loss begins. Optical Coherence Tomography Angiography (OCTA) to identify early retinal vascular changes associated with the disease. One of the most notable studies, published in the journal Neurology, involved over 8,000 cognitively healthy participants. They took a visual sensitivity test, where they had to press a button as soon as they saw a triangle appear in a field of moving dots. Those who later developed dementia performed significantly worse on the test compared to those who remained healthy. The research suggests that visual impairments could be early indicators of cognitive decline, possibly because the amyloid plaques associated with Alzheimer’s may first affect the brain regions tied to vision. In addition, other visual deficits like difficulty distinguishing certain colors or controlling eye movements have also been identified as early signs. For further details, you can check out the full article from the New York Post, which explains the “triangle test” and how it caught Alzheimer’s 12 years early: https://lnkd.in/gNJ9Vf3B This growing body of evidence suggests that vision tests may one day become a standard tool for early Alzheimer’s detection.

Researchers at Lund University have developed a digital cognitive test for diagnosing Alzheimer's disease that is intended for use in primary care. “This digital test, which patients perform on their own with minimal involvement from healthcare personnel, improves the primary care physician's ability to determine who should be further examined by blood tests for Alzheimer's pathology early in the investigation phase,” says Professor Oskar Hansson , who led the study alongside @Pontus Tideman. #alzheimer #research #cognition #diagnosing #pathology https://lnkd.in/dC7bZ3H6

UCI MIND researchers have received an $18 million, five-year grant from the National Institute on Aging (NIA) to conduct a landmark multi-center study on dementia. The award highlights UC Irvine's position as a global leader in Alzheimer's disease and related dementias research. The project will establish the nation's first trial-ready patient group for limbic predominant age-related TDP-43 encephalopathy (LATE), a common but underrecognized condition present in up to 40 percent of older adults' brains. “This study will advance efforts to develop accurate diagnostic tools for LATE and lay the foundation for recruiting participants into future clinical trials targeting this disease,” says S. Ahmad Sajjadi, M.D., Ph.D., associate professor of neurology in the UC Irvine School of Medicine. More: https://bit.ly/465Rl7C UC Irvine School of Medicine

The FDA has approved a subcutaneous form of Leqembi (lecanemab-irmb)—branded as LEQEMBI® IQLIK™—for patients in the early stages of Alzheimer’s disease. Launching October 6, 2025, this once-weekly under-the-skin (subcutaneous) injection may be a treatment option for patients with mild forms of Alzheimer's disease after they have completed the initial 18-month treatment plan of intravenous infusions. Importantly, treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the stage of disease where it has been shown to slow progression in clinical trials. At MIND, our Alzheimer’s Disease & Memory Disorder Center is at the forefront of bringing proven, evidence-based therapies to patients and families. Advances like LEQEMBI® IQLIK™ reflect meaningful progress in the fight against Alzheimer’s. Concerned about cognitive decline? Early evaluation is key. Call 248-553-0010 or visit MINDonline.com to learn more about our Alzheimer’s & Memory care. #Alzheimers #Neurology #MIND #MedicalInnovation #PatientCare #FDA #Leqembi

Did you know? Approximately 65% of dementia cases in Hong Kong are related to Alzheimer's disease. With the elderly population projected to reach roughly 33% by 2064, local research and funding must expand to meet the challenge. Earlier this year, a study at a leading Hong Kong university, in collaboration with Prof. Nick Wang (Founder and Head of R&D at eefit), investigated the effects of far infrared (FIR) radiation on Alzheimer's disease. They reported simultaneous improvement in Alzheimer's hallmark symptoms, namely reductions in beta-amyloid plaques and tau phosphorylation, alongside suppression of neuroinflammation. These effects led to significant improvements in learning, memory, and cognitive function. Although past FIR studies have targeted these symptoms, they were studied separately and lacked standardised delivery, which made it difficult to compare and suggest conclusive evidence for why FIR could benefit cognition. On the other hand, this study used the EEFit Lite as a calibrated, stable FIR emitter (4–20 μm), establishing a repeatable method and strengthening the evidence base. The findings provide peer-reviewed support for industrial and clincial development of eefit FIR technology and enable follow-up studies, replication and optimisation. Following these impressive results, the Dean of the Chinese Medicine Faculty expressed: "For patients with mild cognitive impairment, FIR has the potential to delay disease progression for several years, which would also reduce the burden on medical resources and provide significant assistance to families and caregivers." More clinical studies must be conducted before FIR can be accepted as the ideal alternative treatment option for Alzheimer's disease, but this research paper has unlocked the potential for FIR technology as a new healthcare model. Read more: https://lnkd.in/g6y9YQAy #eefit #healthcare #alzheimers #dementia #farinfrared #research #collaboration #biotech

Impressive work here! "Neurological conditions, including dementia, pose a major public health challenge, contributing to a significant and growing clinical, economic, and societal burden. Traditionally, research and clinical practice have focused on diseases like dementia in isolation. However, in an ageing, multimorbid population, this approach is becoming increasingly inadequate. Recognising brain health as a lifelong attribute influenced by various health determinants, this paper explores the concept of brain health, identifies key challenges in assessing it effectively, and examines how digital biomarkers could provide a versatile measurement framework to enhance monitoring and facilitate earlier intervention. Finally, we outline future directions to help advance definitions of meaningful aspects of brain health integration, and practical adoption of digital biomarkers, enhancing our capacity to measure and preserve ‘brain health capital’ or ‘brain span’ across the lifecourse." Kelly O'Brien Connor McLaughlin George Vradenburg Andy Moose Agustin Ibanez Kana Enomoto Lucy Perez Erica Hutchins Coe Jochen Reiser, M.D., Ph.D. The University of Texas Medical Branch Amy Dittmar Adrian Trömel https://lnkd.in/gxAViT7R

Brain health is rarely about one single thing. For those just starting to notice changes, or for caregivers supporting a loved one, it often comes down to a mix of medical, lifestyle, and social factors all working together. Digital tools like diagnostics, wearables, and mobile health platforms are starting to give us a more complete picture. But the real value is not in the data alone. It is in how we use that information to set meaningful goals for people and their families. Research shows that up to 45 percent of dementia cases could be delayed or even prevented through early intervention. This is where the brain–body connection becomes so important, especially for those beginning to experience change. In dementia, it is rarely one physical cause. It is often many factors that shape daily life and wellbeing. That is why integrated and comprehensive care matters most. Thanks for the share Harris Eyre Dilpriya K. Mangat MD FRCPC MBA NexCerebrum